In clinical continuous glucose monitoring (CGM) performance studies, the accuracy of a CGM system is assessed by comparing its readings with blood glucose (BG) measurements obtained at the same time. Because CGM readings are stored in fixed intervals (typically five minutes) while comparator measurements are performed manually (typically every 15 minutes), CGM readings and comparator measurements may not be perfectly synchronized. This raises the question of how CGM and BG values should be paired if they were recorded at similar but different timestamps.
A literature review on CGM accuracy studies revealed that multiple different methods have been used in past studies: 1
“Linear interpolation”: Linear interpolation is used to fill the gaps between CGM readings (one-minute intervals) and the CGM reading (interpolated or actual) with the same timestamp as the BG value is utilized (14 studies).
“Closest”: The CGM reading that was recorded closest in time to the BG value is paired. This can be simultaneously, before, or after the BG timestamp (30 studies).
“CGM after”: The CGM reading recorded simultaneously or after the BG timestamp is always used (18 studies).
“CGM before”: The CGM reading recorded simultaneously or before the BG timestamp is always used (four studies).
A difference of up to 1.8% in mean absolute relative difference (MARD) was found between methods using data from a recent study of a CGM system with a five-minute sampling interval (Figure 1). 2 Furthermore, these approaches only affect the level of performance observed in CGM performance studies, but not the systems’ clinical usefulness. This considerable variability highlights the need for standardization of the pairing method and also raises the question of the most appropriate method.
Figure 1.
Schematic illustrations of the four pairing methods “linear interpolation” (panel a), “closest” (panel b), “CGM after” (panel c), and “CGM before” (panel d). In this example, CGM recording intervals of five minutes were selected, but the approaches are independent from CGM systems and recording intervals. The mean absolute relative differences (MARD) in the titles were calculated by applying the different pairing methods to data from the same CGM system and comparator measurements collected in a recent CGM performance study. 2
As expected, the “CGM after” method shows the highest (ie, best) accuracy because it can systematically compensate for a CGM system’s time lag and is likely favored by manufacturers for that reason. In contrast, the “CGM before” method leads to the lowest (ie, worst) accuracy as it can exacerbate the time lag. The “linear interpolation” and “closest” methods are a compromise between these two extremes. They are neutral in a technical sense since they do not impact the perceived time lag of the system. However, the “linear interpolation” method can generate CGM readings that are never displayed to the user.
The authors acknowledge that each of the four approaches has its own strengths and limitations, which may be more or less relevant depending on specific goals of CGM performance studies. However, in the interest of making results from different studies more comparable through standardization, the authors recommend using the “closest” pairing method in all future CGM performance evaluations. This recommendation is based on the relative popularity of this method in the literature as well as the fact that the “closest” pairing method is neutral regarding time lag while only pairing actually recorded CGM readings. In case that two CGM readings were recorded equidistant to the BG timestamp, which can occur if the CGM sampling interval is an even number, it is recommended to pair the earlier CGM reading.
Footnotes
Abbreviations: CGM, continuous glucose monitoring; BG, blood glucose.
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: S.P. is an employee of the Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm; Germany (IfDT).
G.F. is the general manager and medical director of the Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm; Germany (IfDT), which carries out clinical studies on its own initiative and on behalf of various companies. G.F./IfDT have received speakers’ honoraria or consulting fees in the last three years Abbott, Berlin Chemie, Boydsense, Dexcom, Glucoset, i-SENS, Lilly, Menarini, Novo Nordisk, Perfood, Pharmasens, Roche, Sinocare, Terumo, Ypsomed.
R.J.S. is chair of the Clinical Chemistry Department of Isala that carries out clinical studies, for example, with medical devices for diabetes therapy on its own initiative and on behalf of various companies. R.J.S. has received speaker’s honoraria or consulting fees in the last three years from Roche and Menarini.
P.D. has received consulting fees in the last three years from Abbott and Pharmasens.
E.E.B. has no disclosures.
M.F. received lecture fees from Menarini.
R.H. is an independent medical & scientific consultant and a former employee of Roche Diabetes Care.
J.J. has been a lecturer/member of the scientific advisory boards at the following companies: Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Medtronic, Nordic InfuCare, Novo Nordisk, and Sanofi.
D.C.K. is a consultant for Afon, Atropos Health, embecta, Glucotrack, Lifecare, Novo, and Thirdwayv.
J.L. has no disclosures.
K.M. has nothing to disclose.
V.M. has acted as consultant and speaker, received research or educational grants from Abbott, Medtronics, Novo Nordisk, Sanofi, Servier, Boehringer Ingelheim, Eli Lilly, Johnson & Johnson, Lifescan, Roche, MSD, Novartis, Aventis, Bayer, USV, Dr. Reddy’s, Sun Pharma, INTAS, Lupin, Glenmark, Zydus, IPCA, Torrent, Cipla, Biocon, Primus, Franco Indian, Wockhartd, Emcure, Mankind, Fourrts, Apex, GSK, and Alembic.
J.H.N. has received research support from Abbott Diagnostics and Roche Diabetes Care.
J.P.—Advisory panel for ROCHE Diabetes Care and Abbott. Speaker fees from Insulet and Dexcom.
E.S. is supported by grants from the US National Institutes of Health (NIH) and has received donated materials related to NIH-supported research from Abbott Diabetes Care, Roche Diagnostics, Siemens Diagnostics, Ortho Clinical Diagnostics, Abbott Diagnostics, Asahi Kasei Pharma Corp, GlycoMark Corp.
A.T. is an Independent scientific consultant. He has received fees for lectures or consultancy fees from Abbott, Berlin Chemie, Dexcom, Evivamed, Menarini, Novo Nordisk, Roche, Sanofi in the last three years.
N.K.T. is a consultant for Roche Diagnostics and Roche Molecular Systems, received honoraria from Nova Biomedical and Thermo Fisher, and Chair (2024-2026), Point-of-Care Testing (POCT) Division, Association for Diagnostics and Laboratory Medicine (ADLM).
L.W. has nothing to disclose.
M.E. is an employee of IfDT.
Funding: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Financial support was provided by Diabetes Center Berne.
ORCID iDs: Stefan Pleus
https://orcid.org/0000-0003-4629-7754
Guido Freckmann
https://orcid.org/0000-0002-0406-9529
Marion Fokkert
https://orcid.org/0000-0002-4687-1157
Rolf Hinzmann
https://orcid.org/0000-0002-8419-4740
Johan Jendle
https://orcid.org/0000-0003-1025-1682
David C. Klonoff
https://orcid.org/0000-0001-6394-6862
Konstantinos Makris
https://orcid.org/0000-0002-7896-9028
Viswanathan Mohan
https://orcid.org/0000-0001-5038-6210
James H. Nichols
https://orcid.org/0000-0002-3652-1612
John Pemberton
https://orcid.org/0000-0002-0730-7879
Elizabeth Selvin
https://orcid.org/0000-0001-6923-7151
Andreas Thomas
https://orcid.org/0000-0002-6549-2793
Nam K. Tran
https://orcid.org/0000-0003-1565-0025
Lilian Witthauer
https://orcid.org/0000-0001-9459-875X
Manuel Eichenlaub
https://orcid.org/0000-0003-2150-3160
References
- 1. Freckmann G, Eichenlaub M, Waldenmaier D, et al. Clinical performance evaluation of continuous glucose monitoring systems: a scoping review and recommendations for reporting. J Diabetes Sci Technol. 2023;17(6):1506-1526. doi: 10.1177/19322968231190941. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Eichenlaub M, Waldenmaier D, Wehrstedt S, et al. Performance of three continuous glucose monitoring systems in adults with type 1 diabetes [published online ahead of print February 4, 2025]. J Diabetes Sci Technol. doi: 10.1177/19322968251315459. [DOI] [PMC free article] [PubMed] [Google Scholar]

